The Quantellect read.As of Nov 19, 2026, 3 active firms cover Century Therapeutics Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $4.00 to $8.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $5.67 sits 312% above the current $1.38. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.12 next quarter toward $-0.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$5.67
+312.1% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.38 current
Highest Target$8.00
Average Target$5.67
Lowest Target$4.00
Detailed analyst forecasts for IPSC
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate IPSC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IPSC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.12
Range $-0.12 – $-0.12 · 2 analysts · +9% YoY
Next period, 2 analysts expect Century Therapeutics Inc to earn $-0.12 a share (range $-0.12 – $-0.12), versus $-0.11 a year earlier. Full-year consensus is $-0.52, growing to $-0.45 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Century Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IPSC.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
No targeton IPSC
Overall win rate
53%
+ Follow
#2
Geulah Livshits
Chardan Capital · Rank #104
Buy
$6.00+336.4% to target
Overall win rate
43%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$5.00+263.6% to target
Overall win rate
33%
+ Follow
#4
Daina Graybosch
Leerink Partners · Rank #396
Neutral
$2.00+45.5% to target
Overall win rate
41%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$4.00+190.9% to target
Overall win rate
29%
+ Follow
IPSC stock forecast FAQ
What is IPSC's average 12-month price target?+
The 3 active firms with a live target average $5.67 for Century Therapeutics Inc over the next 12 months, ranging from a $8.00 high to a $4.00 low, as of Nov 19, 2026.
Is IPSC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IPSC?+
The Street-high target is $8.00 (Mizuho), and the Street-low is $4.00 (Piper Sandler). The average of all 3 active-firm targets is $5.67.
How many active Wall Street firms cover IPSC?+
3 active firms have a recognized rating on Century Therapeutics Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IPSC?+
Among analysts who currently cover IPSC, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy.
What is Century Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.12 per share (range $-0.12 – $-0.12) across 2 analysts. Full-year EPS is projected at $-0.52, rising to $-0.45 the following year.
How much revenue is Century Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IPSC lately?+
As of Nov 19, 2026, 3 of 3 active firms rate IPSC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IPSC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.